Chroma Therapeutics is focused on the R&D of novel small molecule drugs based on chromatin biology and cell accumulation.
Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 5, 2010 | Debt Financing | $15M | 1 | Hercules Capital | — | Detail |
Apr 3, 2006 | Series C | $53M | 1 | Phase4 Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Debt Financing |
Phase4 Ventures | Yes | Series C |